Gedatolisib triplet cut the risk of disease progression or death by 76% vs. fulvestrant. Median progression-free survival improved to 9.3 months with the triplet vs. 2.0 months with fulvestrant. The market's back, and these 3 income stocks are thriving. See them here→ Celcuity Inc.

CELC

<p>Gedatolisib 三聯療法將疾病進展或死亡的風險降低了 76%，與 fulvestrant 相比。中位無進展生存期從 fulvestrant 的 2.0 個月提高至三聯療法的 9.3 個月。市場回暖，這三隻收入股票表現良好。請在此查看→ Celcuity Inc</p>

Celcuity 股票因重度預處理乳腺癌的突破性試驗數據而大幅上漲